ICU Medical (NASDAQ:ICUI) Director Sells $297,933.84 in Stock

ICU Medical, Inc. (NASDAQ:ICUI) Director David Greenberg sold 2,424 shares of ICU Medical stock in a transaction that occurred on Tuesday, May 12th. The stock was sold at an average price of $122.91, for a total transaction of $297,933.84. Following the completion of the sale, the director directly owned 7,960 shares of the company’s stock, valued at $978,363.60. The trade was a 23.34% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.

ICU Medical Stock Down 3.5%

ICUI stock opened at $118.72 on Friday. The stock has a market capitalization of $2.97 billion, a P/E ratio of 64.17, a PEG ratio of 1.77 and a beta of 0.74. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.17 and a current ratio of 2.34. ICU Medical, Inc. has a one year low of $107.00 and a one year high of $160.29. The company has a 50 day moving average price of $125.92 and a two-hundred day moving average price of $138.30.

ICU Medical (NASDAQ:ICUI) last released its earnings results on Thursday, May 7th. The medical instruments supplier reported $1.97 EPS for the quarter, topping the consensus estimate of $1.78 by $0.19. The firm had revenue of $525.77 million during the quarter, compared to analysts’ expectations of $520.65 million. ICU Medical had a net margin of 2.15% and a return on equity of 7.50%. ICU Medical’s revenue for the quarter was down 12.3% on a year-over-year basis. During the same period in the previous year, the company earned $1.72 EPS. ICU Medical has set its FY 2026 guidance at 7.750-8.450 EPS. As a group, sell-side analysts expect that ICU Medical, Inc. will post 6.31 EPS for the current year.

Institutional Trading of ICU Medical

Several institutional investors have recently made changes to their positions in ICUI. Vanguard Group Inc. boosted its position in ICU Medical by 3.4% during the 4th quarter. Vanguard Group Inc. now owns 2,714,746 shares of the medical instruments supplier’s stock worth $387,313,000 after purchasing an additional 89,755 shares during the period. Janus Henderson Group PLC boosted its position in ICU Medical by 4.2% during the 4th quarter. Janus Henderson Group PLC now owns 2,576,756 shares of the medical instruments supplier’s stock worth $367,625,000 after purchasing an additional 103,220 shares during the period. Millennium Management LLC boosted its position in ICU Medical by 173.4% during the 3rd quarter. Millennium Management LLC now owns 1,089,017 shares of the medical instruments supplier’s stock worth $130,638,000 after purchasing an additional 690,694 shares during the period. Dimensional Fund Advisors LP boosted its position in ICU Medical by 6.8% during the 1st quarter. Dimensional Fund Advisors LP now owns 983,802 shares of the medical instruments supplier’s stock worth $127,053,000 after purchasing an additional 63,026 shares during the period. Finally, State Street Corp boosted its position in ICU Medical by 2.8% during the 4th quarter. State Street Corp now owns 942,670 shares of the medical instruments supplier’s stock worth $134,491,000 after purchasing an additional 25,545 shares during the period. 96.10% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several analysts have recently issued reports on ICUI shares. Weiss Ratings raised shares of ICU Medical from a “sell (d)” rating to a “sell (d+)” rating in a research note on Monday. Wall Street Zen raised shares of ICU Medical from a “hold” rating to a “buy” rating in a research note on Saturday, May 9th. KeyCorp lowered their price objective on shares of ICU Medical from $180.00 to $164.00 and set an “overweight” rating for the company in a research note on Monday, April 27th. Piper Sandler lowered their price objective on shares of ICU Medical from $178.00 to $163.00 and set an “overweight” rating for the company in a research note on Friday, April 17th. Finally, Jefferies Financial Group raised shares of ICU Medical to a “strong-buy” rating in a research note on Thursday, May 7th. Two equities research analysts have rated the stock with a Strong Buy rating, two have issued a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, ICU Medical presently has a consensus rating of “Buy” and a consensus price target of $169.00.

ICU Medical Company Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.